Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients
Everolimus extended median progression-free survival from 4.6 to 11.0 months vs. placebo and reduced risk of cancer progression by 65%
02-Jul-2010 -
Novartis announced that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, ...
chemotherapy
clinical trials
gastrointestinal cancer
+3